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Abstract 
Background:  Recently, doubt has been expressed about the value of a history of heart 
failure (HF) hospitalization as a predictor of adverse cardiovascular outcomes in patients with 
HF and preserved ejection fraction (HF-PEF).   
Objectives:  The aim of this study was to investigate N-terminal pro B-type natriuretic 
peptide (NT pro BNP) levels and recent HF hospitalization, as predictors of future events in 
HF-PEF. 
Methods:  We estimated rates and sex- and age-adjusted hazard ratios (HRs) for the 
composite endpoint of cardiovascular death or HF hospitalization, according to history of 
recent HF hospitalization and baseline NT pro BNP level in the Irbesartan in Heart Failure 
with Preserved systolic function trial (I-Preserve).  
Results:  Rates of the composite endpoint in patients with (n=804) and without (n=1963) a 
recent HF hospitalization were 12.78 (95% CI 11.47-14.24) and 4.49 (4.04-4.99) per 100 
person-years, respectively; HR 2.71 (2.33-3.16). For patients with NT pro BNP >360 pg/ml 
(n=1299), the event rate was 11.51 (10.54-12.58) compared to 3.04 (2.63-3.52) per 100 
person-years in those with a lower level of NT pro BNP (n=1468); HR 3.19 (2.68-3.80). In 
patients with no recent HF hospitalization and NT pro BNPd360 pg/ml (n=1187), the event 
rate was 2.43 (2.03-2.90) compared with 17.79 (15.77-20.07) per 100 person-years when both 
risk predictors were present (n=523); HR 6.18 (4.96-7.69). 
Conclusions:  Recent hospitalization for HF or an elevated level of NT pro BNP identified 
patients at higher risk for cardiovascular events and this risk was increased further when both 
factors were present. 
Keywords: heart failure, heart failure with preserved ejection fraction, prognostic markers, 
outcomes, NT pro BNP  
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Abbreviations  
CI Confidence interval 
HF Heart failure 
HF-PEF Heart failure and preserved ejection fraction 
HR Hazard ratio 
I-Preserve the Irbesartan in Heart Failure with Preserved systolic function 
trial 
NYHA New York Heart Association functional class 
NT pro BNP N-terminal pro B-type natriuretic peptide 
TOPCAT the Treatment of Preserved Cardiac Function with an Aldosterone 
Antagonist Trial 
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Introduction 
Although several studies have shown that prior hospitalization for worsening heart failure 
(HF), especially if recent, is a powerful predictor of future non-fatal and fatal cardiovascular 
events in patients with HF and reduced ejection fraction (HF-REF)1-3, the Treatment of 
Preserved Cardiac Function with an Aldosterone Antagonist Trial (TOPCAT)4 has cast doubt 
upon this relationship in patients with HF with preserved ejection fraction (HF-PEF). There 
were two enrolment strata in TOPCAT, with patients eligible for inclusion on the basis of a 
hospitalization within the previous year, not necessarily for HF but during which they 
received treatment for it (n=2464) or, alternatively, by having an elevated plasma 
concentration of natriuretic peptide within the previous 60 days (n = 981). The rate of the 
primary composite endpoint of cardiovascular death, hospitalization for HF or resuscitation 
from cardiac arrest (the latter was a minor component of the composite) was lower in the 
recent-hospitalization stratum (6.0 per 100 patient years in the placebo group) than in the 
natriuretic peptide stratum (8.5 per 100 patient years in the placebo group).4 Moreover, there 
was an interaction between enrolment stratum and treatment effect (p<0.01) whereby 
spironolactone appeared to reduce the primary endpoint in patients included on the basis of a 
natriuretic peptide measurement (placebo: spironolactone hazard ratio [HR] 0.65 [95% CI 
0.49-0.87]) but not in those randomized on the basis of a prior hospitalization (HR 1.01 
[0.84-1.21]). These findings have raised concerns about the value of a history of HF 
hospitalization as a means of enhancing diagnostic certainty and predicting event rates in 
trials of HF-PEF.5 To investigate this issue further, we examined the relationships of recent 
HF hospitalization prior to inclusion and N-terminal pro B-type natriuretic peptide (NT pro 
BNP) levels assessed at baseline with event rates in the Irbesartan in Heart Failure with 
Preserved systolic function trial (I-Preserve).6  
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Methods 
I-Preserve examined the effects of the angiotensin II receptor antagonist, irbesartan on 
morbidity and mortality in patients with HF-PEF; outcomes did not differ between patients 
randomly assigned to irbesartan or placebo.6 In the present study, we analyzed clinical 
outcomes, namely HF hospitalization and cardiovascular death, according to baseline NT pro 
BNP level, history of recent hospitalization for HF, and combinations of these factors. 
 
Patients 
The rationale, design, and results from I-Preserve have been described in detail.7-9 The trial 
enrolled 4028 patients with a left ventricular ejection fraction of at least 45% who were 60 
years of age or older and had HF symptoms corresponding to New York Heart Association 
(NYHA) functional class II to IV. Patients who were in NYHA functional class II were 
required to have a hospitalization for HF in the 6 months before enrollment.  
Although most patients enrolled in I-Preserve had a measurement of NT pro BNP at their 
randomization visit, the result was not available to investigators at the time of enrolment, 
unlike in TOPCAT, and this measurement was not used to determine study eligibility.9 
We restricted our main analysis to patients who were in NYHA functional class III or IV at 
baseline and who had a measurement of NT pro BNP (Figure 1). We excluded patients in 
NYHA class II from the main analysis because of they were all required to have a recent HF 
hospitalization. However, in a sensitivity analysis, we carried out the same analyses in all 
patients with a NT pro BNP measurement, irrespective of NYHA class. 
We report baseline characteristics of patients according to the presence or absence of HF 
hospitalization in the 6 months prior to study inclusion, and baseline level of NT pro BNP, 
dichotomized at 360 pg/ml (the entry threshold for TOPCAT). In the sensitivity analysis, we 
dichotomized NT pro BNP at 300 pg/ml.  
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Outcomes 
We studied the composite outcome of cardiovascular death or HF hospitalization, as well as 
each of the components of this composite, separately. Deaths and hospitalizations were 
adjudicated by an independent end-point committee.  
 
Statistical analyses 
Baseline characteristics are presented as means with standard deviations for continuous 
variables and frequencies and percentages for categorical variables. Differences in baseline 
characteristics according to recent hospitalization for HF and NT pro BNP levels were 
assessed using a chi-squared test for categorical covariates and either two-sided t-tests or 
analyses of variance for continuous variables, as appropriate. Incidence rates of the outcomes 
of interest are presented per 100 person-years, and the risk of HF hospitalization, 
cardiovascular death and the composite outcome were estimated as HRs in age- and sex-
adjusted Cox regression models, and likelihood ratio tests were conducted comparing models 
with and without inclusion of recent HF hospitalization and NT pro BNP levels. In addition, 
we assessed risk estimates in a multivariate analysis previously validated for the I-Preserve 
study8, which included adjustments for age, sex, BMI, ejection fraction, heart rate, systolic 
blood pressure, ischemic etiology, congestion on x-ray, kidney function, blood urea nitrogen, 
neutrophils, and history of atrial fibrillation, myocardial infarction, diabetes, and 
stroke/transient ischemic attack.  
The analyses were repeated using the four specific combinations of the two risk predictors as 
a categorical variable; i) no recent hospitalization for HF + NT pro BNPd360 pg/ml 
(reference), ii) no recent hospitalization for HF + NT pro BNP>360 pg/ml, iii) recent 
hospitalization for HF + NT pro BNPd360 pg/ml, and iv) recent hospitalization for HF + NT 
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pro BNP>360 pg/ml. In a sensitivity analysis including NYHA II patients, the same groups 
were created using a NT pro BNP cut-point of 300 pg/ml. We also performed a subgroup 
analysis on patients with atrial fibrillation to assess whether the prognostic value of elevated 
NT pro BNP (>360 pg/ml) was similar or different in these patients.   
We did not include randomized treatment in our model as irbesartan had no effect on any 
outcome in I-Preserve. All p values are two-sided, and a p value of <0.05 was considered 
significant. All analyses were performed separately for each dataset using Stata version 11 
(Stata Corp. College Station, Texas, USA).  
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Results 
The characteristics of the patients analyzed are listed in Table 1. Patients are grouped 
according to 1) history of HF hospitalization in last 6 months and 2) NT pro BNP levels d 
and >360 pg/ml. 
 
Patients with recent heart failure hospitalization compared to those without 
Of the 2767 patients included in the present analyses, 804 (29%) had a history of recent HF 
hospitalization. There were some notable differences compared to patients without a recent 
HF hospitalization. Patients with a recent HF hospitalization were slightly older (72 vs. 71 
years), had a lower mean estimated glomerular filtration rate (eGFR), twice the prevalence of 
atrial fibrillation (AF), and greater use of diuretics, mineralocorticoid receptor antagonists 
and beta-blockers. The median level of NT pro BNP was significantly higher compared to 
those without a history of recent HF hospitalization (609 vs. 254 pg/ml). 
 
Patients with an elevated NT pro BNP level compared to those without 
Baseline NT pro BNP was >360 pg/ml in 1299 (47%) patients. Patients with an elevated NT 
pro BNP were older (mean age 73 vs. 70 years), more likely to be men (44% vs. 34%), and 
had a markedly lower mean eGFR (63 vs. 74 l/min/1.73m2). They were also more likely to 
have ischemic heart disease (31% vs. 22%) and had a four-fold higher prevalence of AF 
(44% vs. 10%) compared to patients with a NT pro BNP d360 pg/ml. All other comorbidities 
were also more common in patients with a higher NT pro BNP and use of all medications 
listed was more frequent in these patients, with the exception of calcium channel blockers.  
Rates of the composite endpoint of HF hospitalization and cardiovascular death are presented 
in Table 2 and Figure 2. This composite outcome occurred in 674 (24%) patients overall, 
with a rate per 100 patient-years of 6.56 (95% CI 6.08-7.07). 
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Outcomes according to history of HF hospitalization 
In a sex- and age-adjusted Cox regression model, patients with a recent HF hospitalization 
were more than twice as likely to experience the composite outcome of CV death or HF 
hospitalization compared to patients with no history of recent HF hospitalization (HR 2.71 
[2.33-3.16]; p<0.01) (Figure 2). In separate analyses of components of the composite 
endpoint (Table 2 and Figure 3), recent hospitalization for HF was associated with a higher 
risk of both components, although it seemed to be more strongly associated with HF 
hospitalization (HR 3.35 [2.75-4.07]) than with risk of cardiovascular death (HR 2.18 [1.79-
2.65]). Likelihood ratio tests (Table 3) also indicated better improvement of prediction of HF 
hospitalization (χ2=141.7) than cardiovascular death (χ2=58.2) when recent HF 
hospitalization was included in the model. 
 
Outcomes according to natriuretic peptide level 
In a sex- and age-adjusted Cox regression model, patients with a NT pro BNP level >360 
pg/ml were more than three times as likely to experience the composite outcome of CV death 
or HF hospitalization compared to patients with a NT pro BNP level d360 pg/ml (HR 3.19 
[2.68-3.71]; p<0.001) (Figure 2). 
A higher NT pro BNP level was associated with similarly higher risks of HF hospitalization 
(HR 3.50 [2.78-4.40]) and cardiovascular death (HR 3.19 [2.54-4.00]) compared to a NT pro 
BNP level of 360 pg/ml or less (Figure 3), and it also yielded similar improvements in 
prediction in likelihood ratio tests (χ2=130.1 vs. χ2=113.4). 
 
Outcomes according to combinations of the two risk-predictors 
The two risk-predictors overlapped in that 65% of patients with a recent hospitalization for 
HF had a NT pro BNP >360 pg/ml and 40% of those with NT pro BNP>360 pg/ml had also 
Page | 11  
 
had a recent HF hospitalization. We combined the two risk-predictors, to create four distinct 
risk-groups (Table 2). Event rates for the composite endpoint, and HF hospitalization and 
cardiovascular death separately, are shown in this table.   
For the composite outcome, the highest rate (17.79 events per 100 person-years) was 
observed in patients with both a NT pro BNP level >360 pg/ml and a recent HF 
hospitalization. Conversely, the lowest rate (2.42 events per 100 person-years) was observed 
in patients with neither a NT pro BNP >360 pg/ml nor a recent HF hospitalization. The 
composite primary outcome occurred at an intermediate rate in patients with one or the other 
risk-predictor. These patients had a 2-3 fold higher risk of CV death or HF hospitalization 
whereas patients with both a higher NT pro BNP and a recent HF hospitalization had a 6- 
fold higher risk of this outcome (both comparisons to patients with neither risk-predictor) 
(Figure 3). When the two groups with only one of the risk-predictors were compared, a NT 
pro BNP level >360 pg/ml was associated with a higher risk of cardiovascular death than a 
recent HF hospitalization in the prior 6 months (HR 1.63 [1.10-2.42]; p<0.01). We found no 
significant differences for the risk of HF hospitalization and the composite outcome, although 
each risk-predictor alone or combined was more strongly associated with the risk of HF 
hospitalization than CV death. Finally, combining the two risk predictors yielded improved 
risk prediction compared to each of the separate, and more so for the risk of HF 
hospitalization (Table 3). 
 
Outcomes in fully adjusted analyses 
In multivariate Cox regression analyses, with previously validated covariates such as kidney 
function, ejection fraction and atrial fibrillation, the risk estimates associated with prior HF 
hospitalization and elevated NT pro BNP were weakened but remained significantly higher, 
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and the pattern of markedly higher risk in presence of both predictors was consistent with the 
primary analyses. 
 
Sensitivity analyses 
The results of the sensitivity analysis including patients in NYHA II functional class are 
shown in the Appendix. These were entirely consistent with the findings of the main analysis. 
In patients with atrial fibrillation, the higher risks associated with an elevated NT pro BNP, as 
evaluated using the fully adjusted hazard ratios, were similar to those in patients without 
atrial fibrillation, with the possible exception of cardiovascular death. However, the number 
of patients with atrial fibrillation was modest (n=428) and the 95% confidence intervals 
around the hazard ratio point estimates were wide. 
   
Page | 13  
 
Discussion 
In this analysis of the I-Preserve trial, we found that both elevated natriuretic peptide level 
and a history of recent HF hospitalization identified patients at higher risk of HF 
hospitalization, cardiovascular death and the composite of both outcomes. Their combination 
was an even better predictor of risk.  
Patients could therefore be categorized into four distinct risk-groups where those with neither 
an elevated NT pro BNP nor a recent heart failure hospitalization were at lowest risk, those 
with one or other risk-predictor were at intermediate risk (2 to 3-fold higher than patients 
with neither risk-predictor) and patients with both were at highest risk (5 to 8-fold higher than 
patients with neither). NT pro BNP was, however, a more powerful individual predictor of 
future cardiovascular death than recent heart failure hospitalization. In a subgroup analysis, 
we found that the risk associated with a higher NT pro BNP (using the same cut-point of 360 
pg/ml) were, perhaps surprisingly, similarly elevated in patients with and without atrial 
fibrillation for all outcomes examined, with the possible exception of cardiovascular death. 
However, because of the relatively modest number of patients (n=428) with atrial fibrillation 
(and small number of events in these patients), no definitive conclusion can be drawn and it 
remains possible that a higher NT pro BNP threshold would be more appropriate for risk-
prediction in these patients than in patients without atrial fibrillation. In the present study, the 
rate of cardiovascular death or HF hospitalization in patients with an elevated NT pro BNP 
was 11.5 per 100 person years. However, in TOPCAT, it is likely that NT pro BNP was 
primarily used to determine eligibility in patients without a recent HF hospitalization.4 In I-
Preserve, the rate of cardiovascular death or HF hospitalization in patients with an elevated 
NT pro BNP but without a recent HF hospitalization was only 8.2 per 100 person years. This 
rate is similar to that observed in patients randomized through the natriuretic peptide stratum 
into the placebo arm of TOPCAT (8.5 per 100 person years for the slightly broader primary 
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composite endpoint of cardiovascular death, hospitalization for heart failure or resuscitation 
from cardiac arrest).   
What differed substantially between the two trials were the event rates in patients enrolled on 
the basis of a recent HF hospitalization. The rate of cardiovascular death or HF 
hospitalization in these patients in I-Preserve was 12.8 per 100 patient years. This is 
considerably higher than the rate of 6.0 per 100 patient years for the primary composite 
endpoint in those enrolled through the hospitalization stratum in TOPCAT and assigned to 
placebo (also 6.0 per 100 person years in the spironolactone arm). This comparison assumes 
that a NT pro BNP level was not available in patients enrolled in this way in TOPCAT. 
CHARM-Preserved also provides a useful comparison.10 In that trial, in which NT pro BNP 
measurements were not available, the rate of the composite of cardiovascular death or HF 
hospitalization (the same composite as reported here for I-Preserve) was 5.7 per 100 person 
years in patients without a history (at any time) of HF hospitalization and 10.8 per 100 person 
years in those with such a history. In other words, the rate of the same composite outcome in 
patients with prior HF hospitalization was very similar in I-Preserve and CHARM-Preserved 
and both were much higher than in TOPCAT. 
 
We believe that there are 3 potential explanations for this difference in event rate, all of 
which have important implications for the design of future trials in HF-PEF. One possibility 
is that in TOPCAT hospitalization had to be within 12 months whereas in I-Preserve it had to 
be within 6 months. Following HF hospitalization, the increased risk of another event 
diminishes rapidly over time although we don’t believe that a difference of 6 months can 
explain the disparity between rates in I-Preserve and TOPCAT, especially as a history of 
prior HF hospitalization at any time in CHARM-Preserved was associated with almost double 
the rate of the primary composite outcome compared to no such history. A second possibility 
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is the protocol wording related to what was meant by prior hospitalization. In I-Preserve this 
stated:  “A subject will be considered to have been hospitalized for heart failure if the 
primary reason for admission was heart failure and treatment directed specifically for heart 
failure” whereas in TOPCAT the wording was: “At least  one  hospital  admission  in  the  
last  12  months  for  which  heart  failure  was  a  major component  of  the  hospitalization”. 
This subtle difference may have been critically important in that the former required an 
admission for HF whereas the latter accepted an admission with HF i.e. admissions for 
another reason during which patients received treatment for or had symptoms of HF, e.g. AF. 
Such patients may not be at the same risk of future HF events as those who have had a recent 
admission primarily because of HF. Lastly, if patients were enrolled in TOPCAT on the basis 
of a prior hospitalization, despite knowledge of a low natriuretic peptide level, this selection 
bias would have created a group similar to those in I-Preserve with a history of HF 
hospitalization but a NT pro BNP level d360 pg/ml. In I-Preserve, these individuals had a 
primary outcome rate of only 5.9 per 100 patient years compared with 12.8 per 100 patient 
years in all patients with a prior HF hospitalization, irrespective of NT pro BNP level (and a 
rate of 10.8 per 100 patient years in CHARM patients with a prior HF hospitalization, with 
unknown natriuretic peptide levels).  Clearly, 5.9 per 100 patient years is very similar to the 
rate of 6.0 per 100 patient years for the primary composite endpoint in those enrolled on the 
basis of prior hospitalization in TOPCAT. 
 
These findings provide lessons for future trial conduct in HF-PEF. Ease of recruitment into a 
clinical trial always reflects a balance between the restriction of the pool of patients available 
for recruitment imposed by the inclusion and exclusion criteria, the desire to ensure patients 
have the disease in question and the intent to enroll patients at sufficient risk of the pre-
specified efficacy outcome to ensure the study has the statistical power to test its hypothesis. 
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In patients with HF-PEF, a history of prior HF hospitalization (especially if recent) and a 
raised NT pro BNP identify patients at higher risk of CV death or HF hospitalization, 
although NT pro BNP is a somewhat stronger predictor, especially of a robust outcome such 
as cardiovascular mortality. The highest risk patients are those who have both of these 
predictors but such individuals represented only 19% of the total in I-Preserve. Requiring 
both of these for inclusion in a HF-PEF trial is likely to be overly restrictive. However, 47% 
of patients had a high NT pro BNP, 29% had a history of recent HF hospitalization and 57% 
of patients had at least one of these two risk-predictors, placing them at intermediate risk. 
Using one or other of these criteria would greatly expand the pool of available patients but 
with the trade-off of a lower event rate. Importantly, permitting inclusion of patients on the 
basis of prior HF hospitalization despite a known low natriuretic peptide concentration will 
select a relatively low risk group (but one that still has twice the risk of patients without 
either risk predictor). This consideration must be weighed against the difficulty in recruiting 
HF-PEF patients for clinical trials; it took 36 months to recruit patients for I-Preserve and 66 
months in TOPCAT. Patients with neither a high natriuretic peptide level nor a recent HF 
hospitalization have such a low event rate (especially of HF hospitalization) that they 
probably shouldn’t be recruited in event-driven outcome trials, especially as it may also be 
difficult to be certain of the diagnosis HF-PEF in such individuals. Defining what is meant by 
“prior HF hospitalization” is also likely to be critical, and investigators and sponsors should 
consider examination of source documents to verify such events. 
 
As with any study of this type, there are some limitations. I-Preserve had specific inclusion 
and exclusion criteria, therefore our findings may not be generalized to all patients with HF-
PEF. This was also not a pre-specified analysis. Our main analysis excluded patients in 
NYHA functional class II because the protocol required such patients to have a recent history 
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of heart failure hospitalization, although the sensitivity analysis including all patients gave 
similar findings.  
In the present study, we focused on the identification of HF-PEF patients at high risk for HF 
hospitalization and cardiovascular death. However, it is important to remember that these are 
not the only important outcomes in heart failure and improvement in symptoms and quality of 
life are key goals of therapy in HF-PEF.  
Conclusion 
Future trials in HF-PEF should require either a higher natriuretic peptide level or a carefully 
defined history of recent HF hospitalization (or both) in order to identify patients at sufficient 
risk of future events. 
 
Acknowledgements 
Funding sources 
Dr. Kristensen is supported by a Postdoctoral grant from the Danish Independent Research 
Council, and a Research Fellowship from the Heart Failure Association of the European 
Society of Cardiology (ESC).  
 
 
 
 
 
 
 
 
 
Page | 18  
 
References 
1. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for 
congestive heart failure among Medicare beneficiaries. Arch intern med 1997;157:99-104. 
2. Abrahamsson P, Swedberg K, Borer JS, et al. Risk following hospitalization in stable 
chronic systolic heart failure. Eur J Heart Fail 2013;15:885-91. 
3. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart 
failure on subsequent mortality in patients with chronic heart failure. Circulation 
2007;116:1482-7. 
4. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved 
ejection fraction. N Engl J Med 2014;370:1383-92. 
5. McMurray JJ, O'Connor C. Lessons from the TOPCAT trial. N Engl J Med 
2014;370:1453-4. 
6. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure 
and preserved ejection fraction. The New England journal of medicine 2008;359:2456-67. 
7. Carson P, Massie BM, McKelvie R, et al. The Irbesartan in Heart Failure with 
Preserved Systolic Function (I-PRESERVE) trial: Rationale and design. J Card Fail 
2005;11:576-85. 
8. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart 
failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with 
Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011;4:27-35. 
9. McKelvie RS, Komajda M, McMurray J, et al. Baseline plasma NT-proBNP and 
clinical characteristics: results from the irbesartan in heart failure with preserved ejection 
fraction trial. J Card Fail 2010;16:128-34. 
10. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with 
chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved 
Trial. Lancet 2003;362:777-81. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 19  
 
Table 1 Baseline characteristics according to prior hospitalization for Heart Failure, 
and NT pro BNP levels. 
  
  All patients No HF hosp.  
in last 6 months 
HF hosp.  
in last 6 months  
NT pro BNP 
d360 pg/ml 
 NT pro BNP 
>360 pg/ml 
      
N  2767 1963 (71%) 804 (29%) 1468 (53%) 1299 (47%) 
Age, mean – yr   72 ± 7 71 ± 7 72 ± 7* 70 ± 7 73 ± 7* 
Female sex, no. (%)  1694 (61%) 1185 (60%) 509 (63%) 964 (66%) 730 (56%)* 
Race, no (%):    *   
Caucasian  2565 (93%) 1800 (92%) 765 (95%) 1355 (92%) 1210 (93%) 
Black  57 (2%) 40 (2%) 17 (2%) 29 (2%) 28 (2%) 
Other  145 (5%) 123 (6%) 22 (3%) 84 (6%) 61 (5%) 
Ejection fraction  0.60 ± 0.09 0.60 ± 0.09 0.58 ± 0.09* 0.61 ± 0.09 0.58 ± 0.09* 
NYHA class    *  * 
III  2677 (97%) 1924 (98%) 753 (94%) 1437 (98%) 1240 (95%) 
IV  90 (3%) 39 (2%) 51 (6%) 31 (2%) 59 (5%) 
Heart rate /bpm  71 ± 10 70 ± 10 74 ± 11* 71 ± 9 72 ± 11* 
Syst. BP/mm Hg  136 ± 15 137 ± 15 135±14* 137 ± 14 135 ± 15* 
Body mass index  30 ± 5 30 ± 5 29 ± 6 30 ± 5 29 ± 5* 
NT pro BNP, median  323 254 609* 136 955* 
Interquartile range  130-901 111-659 215-1519 73-220 560-1687 
eGFR - l/min/1.73m2  69 ± 19 70 ± 19 65 ± 19* 74 ± 18 63 ± 19* 
Ischemic etiology  728 (26%) 510 (26%) 218 (27%) 323 (22%) 405 (31%)* 
Hypertensive etiology  1756 (64%) 1271 (65%) 485 (60%)* 1043 (71%) 713 (55%)* 
Medical history, no. (%)       
Hypertension  2455 (89%) 1750 (89%) 705 (87%) 1337 (91%) 1118 (86%)* 
Atrial fibrillation  724 (26%) 389 (20%) 335 (42%)* 147 (10%) 577 (44%)* 
Diabetes   779 (28%) 533 (27%) 246 (31%) 387 (26%) 392 (30%)* 
Stroke  272 (10%) 196 (10%) 76 (10%) 120 (8%) 152 (12%)* 
PCI or CABG  375 (14%) 297 (15%) 78 (10%)* 173 (12%) 202 (16%)* 
ICD  8 (0%) 4 (0%) 4 (1%) 3 (0%) 5 (0%) 
Pacemaker  161 (6%) 98 (5%) 63 (8%)* 36 (3%) 125 (10%)* 
Medication, no. (%)       
Loop-diuretic  2247 (81%) 1495 (76%) 752 (94%)* 1133 (77%) 1114 (86%)* 
ACEi/ARB  696 (25%) 486 (25%) 210 (26%) 327 (22%) 369 (28%)* 
Beta-blocker  1579 (57%) 1065 (54%) 514 (64%)* 804 (55%) 775 (60%)* 
Calcium-channel blocker  1139 (41%) 843 (43%) 296 (37%)* 666 (45%) 473 (36%)* 
Mineralocorticoid 
antagonists 
 422 (15%) 210 (11%) 212 (26%)* 161 (11%) 261 (20%)* 
Digoxin  378 (14%) 206 (11%) 172 (21%)* 76 (5%) 302 (23%)* 
 *p-value <0.05 for difference between hospitalization or no hospitalization for heart failure within 6 months,  
   and NT-ProBNP d 360 pg/ml, and >360 pg/ml, respectively 
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 Table 2  Rates of the composite outcome of cardiovascular death or heart failure 
hospitalization, and the two components of the composite separately. 
HF- heart failure, NT pro BNP – N-terminal pro B-type natriuretic peptide, HR –Hazard ratio. 
 
 Number of 
Patients 
Number of 
events 
Event rate 
per 100 py 
  Sex and age 
adjusted HRs 
Fully adjusted  
HRs* 
Composite endpoint 2767 674 (24%) 6.56 (6.08-7.07) -  
      
No HF hospitalization in last 6 mo. 1963 347 (18%) 4.49 (4.04-4.99) 1.00 (ref) 1.00 (ref) 
HF hospitalization in last 6 mo. 804 327 (41%) 12.78 (11.47-14.24) 2.71 (2.33-3.16) 2.05 (1.74-2.43) 
      
NT pro BNPd360 pg/ml 1468 183 (13%) 3.04 (2.63-3.52) 1.00 (ref) 1.00 (ref) 
NT pro BNP>360 pg/ml 1299 491 (38%) 11.51 (10.54-12.58) 3.19 (2.68-3.80) 2.25 (1.85-2.74) 
 
Combinations: 
      
No HF hosp +NT pro BNPd360 pg/ml 1187 120 (10%) 2.42 (2.03-2.90) 1.00 (ref) 1.00 (ref) 
No HF hosp + NT pro BNP>360 pg/ml 776 227 (29%) 8.16 (7.17-9.30) 2.83 (2.26-3.54) 2.24 (1.76-2.88) 
HF hosp + NT pro BNPd360 pg/ml 281 63 (22%) 5.86 (4.58-7.50) 2.42 (1.78-3.29) 2.19 (1.60-3.00) 
HF hosp + NT pro BNP>360 pg/ml 523 264 (50%) 17.79 (15.77-20.07) 6.18 (4.96-7.69) 4.06 (3.16-5.21) 
      
Heart failure hospitalization 2767 404 (15%) 3.93 (3.56-4.33)   
      
No HF hospitalization in last 6 mo. 1963 185 (9%) 2.40 (2.07-2.77) 1.00 (ref) 1.00 (ref) 
HF hospitalization in last 6 mo. 804 219 (27%) 8.56 (7.50-9.77) 3.35 (2.75-4.07) 2.46 (1.98-3.05) 
      
NT pro BNPd360 pg/ml 1468 102 (7%) 1.70 (1.40-2.06) 1.00 (ref) 1.00 (ref) 
NT pro BNP>360 pg/ml 1299 302 (23%) 7.08 (6.33-7.93) 3.50 (2.78-4.40) 2.29 (1.77-2.97) 
 
Combinations: 
     
No HF hosp +NT pro BNPd360 pg/ml 1187 57 (5%) 1.15 (0.89-1.50) 1.00 (ref) 1.00 (ref) 
No HF hosp +  NT pro BNP>360 pg/ml 776 128 (16%) 4.60 (3.87-5.47) 3.34 (2.44-4.59) 2.46 (1.76-3.44) 
HF hosp +  NT pro BNPd360 pg/ml 281 45 (16%) 4.19 (3.12-5.61) 3.59 (2.43-5.31) 3.03 (2.03-4.53) 
HF hosp + NT pro BNP>360 pg/ml 523 174 (33%) 11.73 (10.11-13.61) 8.38 (6.18-11.35) 5.10 (3.62-7.17) 
      
Cardiovascular death 2767 408 (15%) 3.66 (3.23-4.03) -  
      
No HF hospitalization in last 6 mo. 1963 221 (11%) 2.73 (2.39-3.12) 1.00 (ref) 1.00 (ref) 
HF hospitalization in last 6 mo. 804 187 (23%) 6.13 (5.31-7.07) 2.18 (1.79-2.65) 1.64 (1.32-2.03) 
      
NT pro BNPd360 pg/ml 1468 105 (7%) 1.68 (1.39-2.03) 1.00 (ref) 1.00 (ref) 
NT pro BNP>360 pg/ml 1299 303 (23%) 6.20 (5.54-6.93) 3.19 (2.54-4.00) 2.33 (1.81-3.00) 
 
Combinations: 
     
No HF hosp +NT pro BNPd360 pg/ml 1187 75 (6%) 1.48 (1.18-1.86) 1.00 (ref) 1.00 (ref) 
No HF hosp + NT pro BNP>360 pg/ml 776 146 (19%) 4.82 (4.10-5.67) 2.78 (2.10-3.69) 2.25 (1.67-3.04) 
HF hosp + NT pro BNPd360 pg/ml 281 40 (14%) 2.52 (1.76-3.60) 1.71 (1.12-2.61) 1.56 (1.02-2.40) 
HF hosp + NT pro BNP>360 pg/ml 523 157 (30%) 8.44 (7.22-9.87) 4.99 (3.77-6.60) 3.36 (2.44-4.61) 
 *Adjusted for age, sex, BMI, ejection fraction, heart rate, systolic blood pressure, ischemic etiology, congestion on x-ray, 
kidney function, blood urea nitrogen, neutrophils, and history of atrial fibrillation, myocardial infarction, diabetes, and 
stroke/transient ischemic attack.  
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Table 3 Contribution to cardiovascular outcome prediction by recent heart failure 
hospitalization and NT pro BNP in I-Preserve. 
 Variable χ2 P 
Effect of adding variables to model with age and sex only   
Composite outcome   
   HF hospitalization last 6 months  158.5 <0.0001 
   NT pro BNP (360 pg/ml) 190.8 <0.0001 
   Combined  293.1 <0.0001 
    
HF hospitalization:   
   HF hospitalization last 6 months 141.7 <0.0001 
   NT pro BNP (360 pg/ml) 130.1 <0.0001 
   Combined  229.4 <0.0001 
    
Cardiovascular death   
   HF hospitalization last 6 months 58.2  <0.0001 
   NT pro BNP (360 pg/ml) 113.4  <0.0001 
   Combined  144.6 <0.0001 
    
Effect of adding variable to fully adjusted model*   
Composite outcome:   
   HF hospitalization last 6 months 69.5 <0.0001 
   NT pro BNP (360 pg/ml) 70.3 <0.0001 
   Combined  127.1 <0.0001 
    
HF hospitalization:   
   HF hospitalization last 6 months 65.6 <0.0001 
   NT pro BNP (360 pg/ml) 41.6 <0.0001 
   Combined  100.2 <0.0001 
    
Cardiovascular death   
   HF hospitalization last 6 months 19.9 <0.0001 
   NT pro BNP (360 pg/ml) 46.4 <0.0001 
   Combined  60.2 <0.0001 
*Adjusted for age, sex, BMI, ejection fraction, heart rate, systolic blood pressure, ischemic etiology, congestion 
on x-ray, kidney function, blood urea nitrogen, neutrophils, and history of atrial fibrillation, myocardial 
infarction, diabetes, and stroke/transient ischemic attack.  
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Figure legends (short titles and captions). 
 
Figure 1 Flow chart of the study population 
Flow chart of the study population 
 
Figure 2 Risk of the composite outcome 
Sex- and age-adjusted risk of the composite outcome according to recent heart 
failure hospitalization and NT pro BNP level 
 
Figure 3 Risk of heart failure hospitalization and cardiovascular death 
Sex- and age-adjusted risk of heart failure hospitalization and cardiovascular 
death separately, according to recent heart failure hospitalization and NT pro 
BNP level 
 
